Loading...
Docoh

Catalyst Pharmaceuticals (CPRX)

News

From Benzinga Pro
Catalyst Pharmaceuticals Q1 EPS $0.18 Beats $0.14 Estimate, Sales $43.10M Beat $42.75M Estimate
10 May 22
Earnings, News
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.14 by 28.57 percent. This is a 157.14 percent increase over earnings of $0.07 per
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
10 May 22
Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For May 10, 2022
10 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
6 Best-Performing Robinhood Stocks Of 2022
6 May 22
Long Ideas, Small Cap, Top Stories, Trading Ideas
The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year, dropping 43.3%.
This Coal Company's 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin
26 Mar 22
Cryptocurrency, Markets, Movers, Trading Ideas
Alpha Metallurgical Resources Inc (NYSE: AMR) is known as a leading American coal supplier, and over the past year, delivered shocking returns for bullish traders and investors.
Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings
17 Mar 22
Biotech, Earnings, News, Guidance, Health Care, Small Cap, General
Catalyst Pharmaceuticals's Return On Capital Employed Insights
17 Mar 22
Earnings
According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to $38.31 million.
Recap: Catalyst Pharmaceuticals Q4 Earnings
16 Mar 22
Earnings
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Catalyst Pharmaceuticals Q4 EPS $0.09 Misses $0.12 Estimate, Sales $38.31M Beat $38.19M Estimate
16 Mar 22
Earnings, News
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.12 by 25 percent. This is a 18.18 percent decrease over earnings of $0.11 per share
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
16 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For March 16, 2022
16 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million.
Earnings Preview For Catalyst Pharmaceuticals
15 Mar 22
Earnings
Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate that Catalyst Pharmaceuticals will report an earnings per share (EPS) of $0.12.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
13 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Catalyst Pharmaceuticals aAnd KYE Pharmaceuticals Announce Canadian Federal Court Ruling Setting Aside Approval Of Ruzurgi
11 Mar 22
News, Legal
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for
Catalyst Pharma Reports US Patent & Trademark Office Notified Co. Added Patent Covering FIRDAPSE Tablets 10 mg Will Issue On Mar. 8, 2022, 2 Added Patents Will Issue On Mar. 15, 2022
2 Mar 22
Biotech, News, FDA, Legal, General
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio Provides

Press releases

From Benzinga Pro
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
10 May 22
Earnings, Press Releases
Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE® Significant Cash Position of $198 Million and No Funded Debt
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
25 Apr 22
News, Press Releases
CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
16 Mar 22
Earnings, Press Releases
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
11 Mar 22
Health Care, Press Releases
CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
8 Mar 22
Biotech, Health Care, Press Releases, General
CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
3 Mar 22
Biotech, News, Press Releases, General
CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
2 Mar 22
Health Care, Press Releases
Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
24 Feb 22
Biotech, Health Care, Markets, Press Releases, General
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to Kick-Off Rare Disease
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
17 Feb 22
Health Care, Press Releases, General
CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing and commercializing